201 related articles for article (PubMed ID: 32853747)
1. On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites.
Caraceni P; Tufoni M; Zaccherini G; Riggio O; Angeli P; Alessandria C; Neri S; Foschi FG; Levantesi F; Airoldi A; Simone L; Svegliati-Baroni G; Fagiuoli S; Laffi G; Cozzolongo R; Di Marco V; Sangiovanni V; Morisco F; Toniutto P; Gasbarrini A; De Marco R; Piano S; Nardelli S; Elia C; Roncadori A; Baldassarre M; Bernardi M;
J Hepatol; 2021 Feb; 74(2):340-349. PubMed ID: 32853747
[TBL] [Abstract][Full Text] [Related]
2. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites.
Di Pascoli M; Fasolato S; Piano S; Bolognesi M; Angeli P
Liver Int; 2019 Jan; 39(1):98-105. PubMed ID: 30230204
[TBL] [Abstract][Full Text] [Related]
3. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.
Verna EC; Morelli G; Terrault NA; Lok AS; Lim JK; Di Bisceglie AM; Zeuzem S; Landis CS; Kwo P; Hassan M; Manns MP; Vainorius M; Akushevich L; Nelson DR; Fried MW; Reddy KR
J Hepatol; 2020 Sep; 73(3):540-548. PubMed ID: 32243960
[TBL] [Abstract][Full Text] [Related]
4. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial.
Caraceni P; Riggio O; Angeli P; Alessandria C; Neri S; Foschi FG; Levantesi F; Airoldi A; Boccia S; Svegliati-Baroni G; Fagiuoli S; Romanelli RG; Cozzolongo R; Di Marco V; Sangiovanni V; Morisco F; Toniutto P; Tortora A; De Marco R; Angelico M; Cacciola I; Elia G; Federico A; Massironi S; Guarisco R; Galioto A; Ballardini G; Rendina M; Nardelli S; Piano S; Elia C; Prestianni L; Cappa FM; Cesarini L; Simone L; Pasquale C; Cavallin M; Andrealli A; Fidone F; Ruggeri M; Roncadori A; Baldassarre M; Tufoni M; Zaccherini G; Bernardi M;
Lancet; 2018 Jun; 391(10138):2417-2429. PubMed ID: 29861076
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of long-term albumin therapy in the treatment of decompensated cirrhosis.
Khanna D; Kar P; Sahu P
Indian J Gastroenterol; 2024 Apr; 43(2):494-504. PubMed ID: 38722510
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of long-term albumin use in cirrhosis patients from the Mexican healthcare system perspective.
Moctezuma-Velazquez C; Castro-Narro G; Simó P; Viayna E; Aceituno S; Soler M; Torre A
Ann Hepatol; 2022; 27(2):100673. PubMed ID: 35074476
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of normal serum albumin in NASH patients with ascites: a retrospective analysis.
Sourianarayanane A; O'Shea RS; Barnes DS; McCullough AJ
Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):246-53. PubMed ID: 23177511
[TBL] [Abstract][Full Text] [Related]
8. Albumin: Indications in chronic liver disease.
Tufoni M; Zaccherini G; Caraceni P; Bernardi M
United European Gastroenterol J; 2020 Jun; 8(5):528-535. PubMed ID: 32213034
[TBL] [Abstract][Full Text] [Related]
9. Serum Albumin Can Identify Patients With Compensated Cirrhosis With a Good Prognosis.
Ripoll C; Bari K; Garcia-Tsao G
J Clin Gastroenterol; 2015 Aug; 49(7):613-9. PubMed ID: 25203362
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
China L; Freemantle N; Forrest E; Kallis Y; Ryder SD; Wright G; Portal AJ; Becares Salles N; Gilroy DW; O'Brien A;
N Engl J Med; 2021 Mar; 384(9):808-817. PubMed ID: 33657293
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis.
Bajaj JS; Tandon P; OʼLeary JG; Biggins SW; Wong F; Kamath PS; Garcia-Tsao G; Maliakkal B; Lai JC; Fallon M; Thuluvath P; Vargas HE; Subramanian RM; Thacker LR; Reddy RK
Am J Gastroenterol; 2018 Sep; 113(9):1339. PubMed ID: 29880972
[TBL] [Abstract][Full Text] [Related]
12. TIPS for management of refractory ascites: response and survival are both unpredictable.
Thuluvath PJ; Bal JS; Mitchell S; Lund G; Venbrux A
Dig Dis Sci; 2003 Mar; 48(3):542-50. PubMed ID: 12757168
[TBL] [Abstract][Full Text] [Related]
13. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
14. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial.
Solà E; Solé C; Simón-Talero M; Martín-Llahí M; Castellote J; Garcia-Martínez R; Moreira R; Torrens M; Márquez F; Fabrellas N; de Prada G; Huelin P; Lopez Benaiges E; Ventura M; Manríquez M; Nazar A; Ariza X; Suñé P; Graupera I; Pose E; Colmenero J; Pavesi M; Guevara M; Navasa M; Xiol X; Córdoba J; Vargas V; Ginès P
J Hepatol; 2018 Dec; 69(6):1250-1259. PubMed ID: 30138685
[TBL] [Abstract][Full Text] [Related]
15. Transferrin as a predictor of survival in cirrhosis.
Viveiros A; Finkenstedt A; Schaefer B; Mandorfer M; Scheiner B; Lehner K; Tobiasch M; Reiberger T; Tilg H; Edlinger M; Zoller H
Liver Transpl; 2018 Mar; 24(3):343-351. PubMed ID: 29149510
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of tumour markers and serum-ascites albumin gradient in the diagnosis of malignancy-related ascites.
Chen SJ; Wang SS; Lu CW; Chao Y; Lee FY; Lee SD; Wu SL; Cherng KL; Lo KJ
J Gastroenterol Hepatol; 1994; 9(4):396-400. PubMed ID: 7948823
[TBL] [Abstract][Full Text] [Related]
17. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis.
Ginès P; Uriz J; Calahorra B; Garcia-Tsao G; Kamath PS; Del Arbol LR; Planas R; Bosch J; Arroyo V; Rodés J
Gastroenterology; 2002 Dec; 123(6):1839-47. PubMed ID: 12454841
[TBL] [Abstract][Full Text] [Related]
18. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo.
Fernández-Esparrach G; Guevara M; Sort P; Pardo A; Jiménez W; Ginès P; Planas R; Lebrec D; Geuvel A; Elewaut A; Adler M; Arroyo V
J Hepatol; 1997 Mar; 26(3):614-20. PubMed ID: 9075669
[TBL] [Abstract][Full Text] [Related]
19. Albumin May Prevent the Morbidity of Paracentesis-Induced Circulatory Dysfunction in Cirrhosis and Refractory Ascites: A Pilot Study.
Tan HK; James PD; Wong F
Dig Dis Sci; 2016 Oct; 61(10):3084-3092. PubMed ID: 27048451
[TBL] [Abstract][Full Text] [Related]
20. Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection.
El-Sherif O; Jiang ZG; Tapper EB; Huang KC; Zhong A; Osinusi A; Charlton M; Manns M; Afdhal NH; Mukamal K; McHutchison J; Brainard DM; Terrault N; Curry MP
Gastroenterology; 2018 Jun; 154(8):2111-2121.e8. PubMed ID: 29535028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
